Table 1.
Demographic and Clinical Characteristics
| Patient characteristicsa | All patients (N = 2272) | Patients who received temozolomide only (N = 89) | Patients who received radiation therapy only (N = 313) | Patients who received temozolomide and radiation therapy (N = 841) | Patients who did not receive temozolomide or radiation therapy (N = 1029) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age, yrs, mean (SD) | 56.9 (14.5) | 55.3 (15.1) | 59.8 (14.1) | 56.7 (12.1) | 56.3 (16.2) | |||||
| Age-group | ||||||||||
| 18–34 yrs, N (%) | 181 (8) | 9 (10.1) | 20 (6.4) | 38 (4.5) | 114 (11.1) | |||||
| 35–44 yrs, N (%) | 260 (11.4) | 13 (14.6) | 30 (9.6) | 79 (9.4) | 138 (13.4) | |||||
| 45–54 yrs, N (%) | 503 (22.1) | 18 (20.2) | 54 (17.3) | 228 (27.1) | 203 (19.7) | |||||
| 55–64 yrs, N (%) | 648 (28.5) | 23 (25.8) | 73 (23.3) | 303 (36) | 249 (24.2) | |||||
| ≥65 yrs, N (%) | 680 (29.9) | 26 (29.2) | 136 (43.5) | 193 (22.9) | 325 (31.6) | |||||
| Female sex, N (%) | 838 (36.9) | 32 (36) | 102 (32.6) | 251 (29.8) | 453 (44) | |||||
| Urban residence, N (%) | 1936 (85.2) | 72 (80.9) | 263 (84) | 704 (83.7) | 897 (87.2) | |||||
| Health plan type | ||||||||||
| Indemnity, N (%) | 482 (21.2) | 15 (16.9) | 82 (26.2) | 145 (17.2) | 240 (23.3) | |||||
| PPO, N (%) | 1142 (50.3) | 43 (48.3) | 147 (47) | 453 (53.9) | 499 (48.5) | |||||
| HMO, N (%) | 312 (13.7) | 21 (23.6) | 42 (13.4) | 103 (12.2) | 146 (14.2) | |||||
| POS, N (%) | 238 (10.5) | 6 (6.7) | 32 (10.2) | 94 (11.2) | 106 (10.3) | |||||
| Other/unknown, N (%) | 98 (4.3) | 4 (4.5) | 10 (3.2) | 46 (5.5) | 38 (3.7) | |||||
| Comorbid conditions | ||||||||||
| Anemia, N (%) | 93 (4.1) | 1 (1.1) | 13 (4.2) | 23 (2.7) | 56 (5.4) | |||||
| Anxiety, N (%) | 120 (5.3) | 6 (6.7) | 13 (4.2) | 45 (5.4) | 56 (5.4) | |||||
| Aphasia, N (%) | 69 (3) | 6 (6.7) | 14 (4.5) | 27 (3.2) | 22 (2.1) | |||||
| Cerebrovascular disease/stroke, N (%) | 458 (20.2) | 11 (12.4) | 74 (23.6) | 179 (21.3) | 194 (18.9) | |||||
| Cognitive deficiency, changes, or memory loss, N (%) | 127 (5.6) | 2 (2.2) | 15 (4.8) | 49 (5.8) | 61 (5.9) | |||||
| Depression, N (%) | 123 (5.4) | 6 (6.7) | 16 (5.1) | 36 (4.3) | 65 (6.3) | |||||
| Fatigue, N (%) | 235 (10.3) | 7 (7.9) | 31 (9.9) | 92 (10.9) | 105 (10.2) | |||||
| Headache, N (%) | 502 (22.1) | 12 (13.5) | 54 (17.3) | 212 (25.2) | 224 (21.8) | |||||
| Hemiparesis/hemiplegia, N (%) | 50 (2.2) | 1 (1.1) | 5 (1.6) | 21 (2.5) | 23 (2.2) | |||||
| Insomnia, N (%) | 34 (1.5) | 1 (1.1) | 3 (1) | 11 (1.3) | 19 (1.8) | |||||
| Seizures/epilepsy, N (%) | 430 (18.9) | 29 (32.6) | 61 (19.5) | 159 (18.9) | 181 (17.6) | |||||
| Medication use | ||||||||||
| Antianxiety, N (%) | 414 (18.2) | 12 (13.5) | 52 (16.6) | 141 (16.8) | 209 (20.3) | |||||
| Anticonvulsants, N (%) | 783 (34.5) | 38 (42.7) | 109 (34.8) | 314 (37.3) | 322 (31.3) | |||||
| Antidepressants, N (%) | 406 (17.9) | 20 (22.5) | 47 (15) | 130 (15.5) | 209 (20.3) | |||||
| Antiemetics, N (%) | 151 (6.6) | 6 (6.7) | 20 (6.4) | 54 (6.4) | 71 (6.9) | |||||
| Corticosteroids/glucocorticosteroids, N (%) | 913 (40.2) | 35 (39.3) | 138 (44.1) | 366 (43.5) | 374 (36.3) | |||||
| Pain medications (ie, NSAIDs/COX-2 inhibitors), N (%) | 304 (13.4) | 12 (13.5) | 46 (14.7) | 112 (13.3) | 134 (13) | |||||
| Pain medications (ie, narcotic analgesics), N (%) | 593 (26.1) | 16 (18) | 85 (27.2) | 212 (25.2) | 280 (27.2) | |||||
| Sedatives/hypnotics, N (%) | 218 (9.6) | 8 (9) | 32 (10.2) | 77 (9.2) | 101 (9.8) | |||||
| Survival time/death estimatesb | ||||||||||
| Mean survival, days (SD) | 592.6 | 499.1 | 474.8 | 462.9 | 584.4 | 492.1 | 508.6 | 361.7 | 674 | 581.3 |
| Median survival, days | 456 | 331 | 415 | 426 | 529 | |||||
| Patients alive at end of follow-up, N (%) | 1177 (51.8) | 43 (48.3) | 128 (40.9) | 269 (32) | 737 (71.6) | |||||
| Mean survival, days (SD) | 809.1 | 532.7 | 654 | 551.2 | 891.6 | 524.3 | 682 | 437.9 | 850.2 | 555.5 |
| Median survival, days | 668 | 447 | 865.5 | 556 | 748 | |||||
| Observed deaths, N (%) | 1095 (48.2) | 46 (51.7) | 185 (59.1) | 572 (68) | 292 (28.4) | |||||
| Mean survival, days (SD) | 359.9 | 327.9 | 307.2 | 275.7 | 371.9 | 331.5 | 427 | 285.6 | 229.2 | 369.4 |
| Median survival, days | 272 | 228.5 | 259 | 373.5 | 72 | |||||
a
Patient demographic characteristics are presented as of the index date. Clinical characteristics are related to the 6 months before the index.
b
All survival time estimates measure survival time from index date. Patients who did not die during the available follow-up were included in the analysis and were censored as of the end of their enrollment.
COX indicates cyclooxygenase; NSAID, nonsteroidal anti-inflammatory drug; POS, point of service; PPO, preferred provider organization; SD, standard deviation.